Immunohistochemistry Market Insight and Trends 2030

The global Immunohistochemistry market size is expected to be worth around US$ 5.07 billion by 2030, according to a new report by Vision Research Reports.

The global Immunohistochemistry market size was valued at US$ 2.28 billion in 2020 and is anticipated to grow at a CAGR of 7.2% during forecast period 2021 to 2030.

Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/39077

Growth Factors

The high demand for accurate data has driven several technological advancements in (immunohistochemistry) IHC techniques, resulting in the delivery of precise and contextual data analyses. The emergence of various advanced techniques, such as multiplex IHC, computational pathology, and next-generation IHC, is driving the market for immunohistochemistry.

IHC protocols have gained popularity in the field of clinical pathology, especially in the subspecialties of oncologic pathology, hematopathology, and neuropathology. The technique has played a vital role in shaping cancer diagnostics. Thus, the growing prevalence of cancer is expected to increase the demand for immunohistochemistry, thus contributing to market growth.

Report Coverage

Report Scope Details
Market Size US$ 5.07 billion by 2030
Growth Rate CAGR of 7.2% From 2021 to 2030
Largest Market North America
Base Year 2021
Forecast Period 2021 to 2030
Segments Covered Product, Application, End-use
Regional Scope North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Mentioned Thermo Fisher Scientific Inc.; F. Hoffmann-La Roche Ltd.; Merck KGaA; Danaher Corporation; PerkinElmer, Inc.; Bio-Rad Laboratories, Inc.; Cell Signaling Technology, Inc.; Bio SB; Abcam plc.; Agilent Technologies, Inc.

By Product Analysis

The antibodies segment captured the largest revenue share of over 30.0% in 2020 owing to the vital usage of antibodies in disease diagnosis and drug testing. The monoclonal antibodies and antibody-related products such as Fc-fusion, antibody fragments, and antibody-drug conjugates have become the dominating product class in terms of usage rate.

Kits are anticipated to expand at the fastest CAGR throughout the forecast period. The use of kits reduces a lot of efforts during the IHC procedure as it eliminates the selection procedure for use of an appropriate combination of antibodies and stains against a tissue sample.

By Application Analysis

The diagnostics segment accounted for the largest revenue share of over 50.0% in 2020 and is anticipated to maintain its lead over the forecast period. Immunohistochemistry (IHC) tests are widely used for the diagnosis of a wide range of chronic conditions, such as cancer, cardiovascular diseases, infectious diseases, diabetes mellitus, autoimmune diseases, and nephrological diseases.

The growing prevalence of chronic diseases is anticipated to drive the diagnostics segment. According to data published by the American Cancer Society, around 1.9 million new cancer cases are expected to be reported in the U.S. in 2021. With a rise in the number of cancer cases, the need for IHC techniques for rapid and efficient diagnosis is high.

Thus, rising R&D activities by pharmaceutical companies for research and development of innovative drugs are anticipated to increase the demand for IHC solutions and drive the segment.

By End-use Analysis

Hospitals and diagnostic laboratories accounted for the largest revenue share of over 50.0% owing to the high volume of IHC tests carried out in hospitals settings. Furthermore, with the constant changes in the healthcare industry, the need for hospitals with advanced facilities has also increased, which is expected to drive the revenue flow in this segment.

Research institutes are expected to register a lucrative CAGR during the forecast period. This is because the technique offers several advantages over conventionally used staining techniques in pharmaceutical R&D.

The growth can be also attributed to the wide adoption of IHC techniques in drug testing by research institutes. The technique allows the evaluation of biomarker distribution and localization and different protein expressions in varied biological tissue sections, which is conducted in research settings.

By Regional Analysis

North America dominated the market in 2020 with a revenue share of over 45.0%. Key factors contributing to the regional market growth include the local presence of major market players, easy availability of IHC solutions, higher adoption of technologically advanced IHC instruments, and entry of newer IHC solutions.

Asia Pacific is expected to witness the fastest growth during the forecast period. This is primarily due to the expansion of the geographic footprint of the global players in the Asian markets.

Key Players

  • Thermo Fisher Scientific Inc.
  • F. Hoffmann-La Roche Ltd.
  • Merck KGaA
  • Danaher Corporation
  • Perkinelmer, Inc.
  • Bio-Rad Laboratories, Inc.
  • Cell Signaling Technology, Inc.
  • Bio SB
  • Agilent Technologies, Inc.
  • Abcam plc.

Market Segmentation

  • By Product
    • Antibodies
      • Primary Antibodies
      • Secondary Antibodies
    • Equipment
      • Slide Staining System
      • Tissue Microarrays
      • Tissue Processing Systems
      • Slide Scanners
      • Others
    • Reagents
      • Histological stains
      • Blocking Sera and Reagents
      • Chromogenic Substrates
      • Fixation Reagents
      • Stabilizers
      • Organic Solvents
      • Proteolytic Enzymes
      • Diluents
    • Kits
  • By Application
    • Diagnostics
      • Cancer
      • Infectious Diseases
      • Cardiovascular Diseases
      • Autoimmune Diseases
      • Diabetes Mellitus
      • Nephrological Diseases
    • Drug Testing
  • by End-use
    • Hospitals & Diagnostic Laboratories
    • Research Institutes
    • Others
  • Regional
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
    • Asia Pacific
      • Japan
      • China
      • India
      • South Korea
      • Australia
      • Singapore
    • Latin America
      • Brazil
      • Mexico
      • Argentina
    • Middle East & Africa
      • South Africa
      • Saudi Arabia
      • UAE

Table of Contents

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Immunohistochemistry Market, By Product

7.1.  Immunohistochemistry Market, by Product, 2021-2030

7.1.1.    Antibodies

7.1.1.1.        Market Revenue and Forecast (2017-2030)

7.1.2.    Equipment

7.1.2.1.        Market Revenue and Forecast (2017-2030)

7.1.3.    Reagents

7.1.3.1.        Market Revenue and Forecast (2017-2030)

7.1.4.    Kits

7.1.4.1.        Market Revenue and Forecast (2017-2030)

Chapter 8.  Global Immunohistochemistry Market, By Application

8.1.  Immunohistochemistry Market, by Application, 2021-2030

8.1.1.    Diagnostics

8.1.1.1.        Market Revenue and Forecast (2017-2030)

8.1.2.    Drug Testing

8.1.2.1.        Market Revenue and Forecast (2017-2030)

Chapter 9.  Global Immunohistochemistry Market, By End User

9.1.  Immunohistochemistry Market, by End User, 2021-2030

9.1.1.    Hospitals & Diagnostic Laboratories

9.1.1.1.        Market Revenue and Forecast (2017-2030)

9.1.2.    Research Institutes

9.1.2.1.        Market Revenue and Forecast (2017-2030)

Chapter 10.      Global Immunohistochemistry Market, Regional Estimates and Trend Forecast

10.1.        North America

10.1.1.  Market Revenue and Forecast, by Product (2017-2030)

10.1.2.  Market Revenue and Forecast, by Application (2017-2030)

10.1.3.  Market Revenue and Forecast, by End User (2017-2030)

10.1.4.  U.S.

10.1.4.1.      Market Revenue and Forecast, by Product (2017-2030)

10.1.4.2.      Market Revenue and Forecast, by Application (2017-2030)

10.1.4.3.      Market Revenue and Forecast, by End User (2017-2030)

10.1.5.  Rest of North America

10.1.5.1.      Market Revenue and Forecast, by Product (2017-2030)

10.1.5.2.      Market Revenue and Forecast, by Application (2017-2030)

10.1.5.3.      Market Revenue and Forecast, by End User (2017-2030)

10.2.        Europe

10.2.1.  Market Revenue and Forecast, by Product (2017-2030)

10.2.2.  Market Revenue and Forecast, by Application (2017-2030)

10.2.3.  Market Revenue and Forecast, by End User (2017-2030)

10.2.4.  UK

10.2.4.1.      Market Revenue and Forecast, by Product (2017-2030)

10.2.4.2.      Market Revenue and Forecast, by Application (2017-2030)

10.2.4.3.      Market Revenue and Forecast, by End User (2017-2030)

10.2.5.  Germany

10.2.5.1.      Market Revenue and Forecast, by Product (2017-2030)

10.2.5.2.      Market Revenue and Forecast, by Application (2017-2030)

10.2.5.3.      Market Revenue and Forecast, by End User (2017-2030)

10.2.6.  France

10.2.6.1.      Market Revenue and Forecast, by Product (2017-2030)

10.2.6.2.      Market Revenue and Forecast, by Application (2017-2030)

10.2.6.3.      Market Revenue and Forecast, by End User (2017-2030)

10.2.7.  Rest of Europe

10.2.7.1.      Market Revenue and Forecast, by Product (2017-2030)

10.2.7.2.      Market Revenue and Forecast, by Application (2017-2030)

10.2.7.3.      Market Revenue and Forecast, by End User (2017-2030)

10.3.        APAC

10.3.1.  Market Revenue and Forecast, by Product (2017-2030)

10.3.2.  Market Revenue and Forecast, by Application (2017-2030)

10.3.3.  Market Revenue and Forecast, by End User (2017-2030)

10.3.4.  India

10.3.4.1.      Market Revenue and Forecast, by Product (2017-2030)

10.3.4.2.      Market Revenue and Forecast, by Application (2017-2030)

10.3.4.3.      Market Revenue and Forecast, by End User (2017-2030)

10.3.5.  China

10.3.5.1.      Market Revenue and Forecast, by Product (2017-2030)

10.3.5.2.      Market Revenue and Forecast, by Application (2017-2030)

10.3.5.3.      Market Revenue and Forecast, by End User (2017-2030)

10.3.6.  Japan

10.3.6.1.      Market Revenue and Forecast, by Product (2017-2030)

10.3.6.2.      Market Revenue and Forecast, by Application (2017-2030)

10.3.6.3.      Market Revenue and Forecast, by End User (2017-2030)

10.3.7.  Rest of APAC

10.3.7.1.      Market Revenue and Forecast, by Product (2017-2030)

10.3.7.2.      Market Revenue and Forecast, by Application (2017-2030)

10.3.7.3.      Market Revenue and Forecast, by End User (2017-2030)

10.4.        MEA

10.4.1.  Market Revenue and Forecast, by Product (2017-2030)

10.4.2.  Market Revenue and Forecast, by Application (2017-2030)

10.4.3.  Market Revenue and Forecast, by End User (2017-2030)

10.4.4.  GCC

10.4.4.1.      Market Revenue and Forecast, by Product (2017-2030)

10.4.4.2.      Market Revenue and Forecast, by Application (2017-2030)

10.4.4.3.      Market Revenue and Forecast, by End User (2017-2030)

10.4.5.  North Africa

10.4.5.1.      Market Revenue and Forecast, by Product (2017-2030)

10.4.5.2.      Market Revenue and Forecast, by Application (2017-2030)

10.4.5.3.      Market Revenue and Forecast, by End User (2017-2030)

10.4.6.  South Africa

10.4.6.1.      Market Revenue and Forecast, by Product (2017-2030)

10.4.6.2.      Market Revenue and Forecast, by Application (2017-2030)

10.4.6.3.      Market Revenue and Forecast, by End User (2017-2030)

10.4.7.  Rest of MEA

10.4.7.1.      Market Revenue and Forecast, by Product (2017-2030)

10.4.7.2.      Market Revenue and Forecast, by Application (2017-2030)

10.4.7.3.      Market Revenue and Forecast, by End User (2017-2030)

10.5.        Latin America

10.5.1.  Market Revenue and Forecast, by Product (2017-2030)

10.5.2.  Market Revenue and Forecast, by Application (2017-2030)

10.5.3.  Market Revenue and Forecast, by End User (2017-2030)

10.5.4.  Brazil

10.5.4.1.      Market Revenue and Forecast, by Product (2017-2030)

10.5.4.2.      Market Revenue and Forecast, by Application (2017-2030)

10.5.4.3.      Market Revenue and Forecast, by End User (2017-2030)

10.5.5.  Rest of LATAM

10.5.5.1.      Market Revenue and Forecast, by Product (2017-2030)

10.5.5.2.      Market Revenue and Forecast, by Application (2017-2030)

10.5.5.3.      Market Revenue and Forecast, by End User (2017-2030)

Chapter 11.  Company Profiles

11.1.              Thermo Fisher Scientific Inc.

11.1.1.  Company Overview

11.1.2.  Product Offerings

11.1.3.  Financial Performance

11.1.4.  Recent Initiatives

11.2.              F. Hoffmann-La Roche Ltd.

11.2.1.  Company Overview

11.2.2.  Product Offerings

11.2.3.  Financial Performance

11.2.4.  Recent Initiatives

11.3.              Merck KGaA

11.3.1.  Company Overview

11.3.2.  Product Offerings

11.3.3.  Financial Performance

11.3.4.  Recent Initiatives

11.4.              Danaher Corporation

11.4.1.  Company Overview

11.4.2.  Product Offerings

11.4.3.  Financial Performance

11.4.4.  Recent Initiatives

11.5.              Perkinelmer, Inc.

11.5.1.  Company Overview

11.5.2.  Product Offerings

11.5.3.  Financial Performance

11.5.4.  Recent Initiatives

11.6.              Bio-Rad Laboratories, Inc.

11.6.1.  Company Overview

11.6.2.  Product Offerings

11.6.3.  Financial Performance

11.6.4.  Recent Initiatives

11.7.              Cell Signaling Technology, Inc.

11.7.1.  Company Overview

11.7.2.  Product Offerings

11.7.3.  Financial Performance

11.7.4.  Recent Initiatives

11.8.              Bio SB

11.8.1.  Company Overview

11.8.2.  Product Offerings

11.8.3.  Financial Performance

11.8.4.  Recent Initiatives

11.9.              Agilent Technologies, Inc.

11.9.1.  Company Overview

11.9.2.  Product Offerings

11.9.3.  Financial Performance

11.9.4.  Recent Initiatives

11.10.           Abcam plc.

11.10.1.               Company Overview

11.10.2.               Product Offerings

11.10.3.               Financial Performance

11.10.4.               Recent Initiatives

Chapter 12.  Research Methodology

12.1.              Primary Research

12.2.              Secondary Research

12.3.              Assumptions

Chapter 13.  Appendix

13.1.              About Us

13.2.              Glossary of Terms

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/39077

Contact Us:

Vision Research Reports

Call: +1 9197 992 333

Email: sales@visionresearchreports.com

Leave a Reply

Your email address will not be published. Required fields are marked *